Yong Yu - 14 Mar 2025 Form 4 Insider Report for GENELUX Corp (GNLX)

Role
VP, Clinical Trial Operations
Signature
/s/ Sean Ryder, Esq., Attorney-in-Fact
Issuer symbol
GNLX
Transactions as of
14 Mar 2025
Transactions value $
$0
Form type
4
Filing time
17 Apr 2025, 16:56:26 UTC
Previous filing
20 Dec 2024
Next filing
13 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GNLX Common Stock Award $0 +13.4K +33.48% $0.00 53.2K 14 Mar 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of March 14, 2025.